Cambridge Neuroscience, Inc.

Other

Cornell University

Wyeth

Cambridge Neurosciences, Inc.

Stanley M Goldin

N Laxma Reddy

Andrew Gannett Knapp

Subbarao Katragadda

Lain-Yen Hu

James B Fischer

Lee David Margolin

Graham J Durant

Sharad S Magar

David Berlove

Elizabeth Yost

Wenhong Fan

Jun Qing Guo

Nagesh K Mahanthappa

Kazumi Kobayashi

Mark Andrew Marchionni

David I Gwynne

Robert N McBurney

Kevin D McCormick

Olivia Bermingham-McDonogh

Lain-Hu Hu

Deborah Daly

James Fisher

Laxma Reddy

Juo Qing Guo

Andy Knapp

Eric Fine

Judith Sudhalter

The present invention provides therapeutically useful substituted guanidines, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such guanidines.

Therapeutic guanidines

The present invention relates to methods of affecting cellular communication in a vertebrate. The communication is affected by the administration of a neuregulin to a vertebrate, where the neuregulin interacts with a first cell type which results in the production of a product (i.e., Product A). This product, in turn, affects the function of a second cell type. Methods are disclosed in which the affect in function of the second cell type, described above, results in the production of a second product (i.e., Product B) which, in turn, can affect the function of the first cell type or a third cell type. Additional methods are included for treatment of disorders involving an altered or inadequate level of production of a product involved in cellular communication.

Use of neuregulins as modulators of cellular communication

Modulators of neurotransmitter release including substituted guanidines, N'-aminoguanidines, and N,N'N',N''-tetrasubstituted hydrazinedicarboximidamides, and pharmaceutical compositions thereof are disclosed. Also disclosed are methods involving the use of such neurotransmitter release modulators for the treatment or prevention of pathophysiologic conditions characterized by the release of excessive or inappropriate levels of neurotransmitters. Also disclosed are screening assays for compounds which selectively inhibit glutamate release. Also disclosed are methods of blocking voltage sensitive sodium and calcium channels in mammalian nerve cells.

Substituted aminoguanidines and methods of use thereof

The present invention provides N,N'-diaryl substituted guanidines having therapeutic utility. The compounds of the present invention are represented by the formula: ##STR1## wherein R and R.sup.1 represent hydrogen or other group and Ar and Ar.sup.1 represent selected aryl groups, and at least one being acenaphthyl.

Hydrazinedicarboximidamide compounds and pharmaceutical composition

Substituted guanidines and derivatives thereof as modulators of

Substituted hydrazinedicarboximidamides and methods of use thereof

Aminoguanidines and methods of use of same

This invention comprises devices and methods for producing a composite microporous membrane specifically tailored to be useful for optimizing the delivery of macromolecules to a therapeutic target.

Device for delivery of substances and methods of use thereof

Acenaphthyl substituted guanidines and methods of use thereof

Growing community of inventors

Lexington, MA, United States of America

Stanley M Goldin